ClearPoint Neuro/$CLPT
1D1W1MYTD1Y5YMAX
Capital at risk
About ClearPoint Neuro
ClearPoint Neuro Inc is a commercial-stage medical device company that develops and commercializes integrated systems used in minimally invasive neurosurgical procedures in the brain. The company's business consists of two integrated components: a business providing medical devices for neurosurgical applications, and a business focused on partnerships in the biologics and drug delivery space. The Company operates in one reportable segment.
- Ticker
- $CLPT
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 172
- Headquarters
- Solana Beach, United States
- Website
- www.clearpointneuro.com
ClearPoint Neuro Metrics
BasicAdvanced
$349M
-
-$1.18
1.27
-
Price and volume
Market cap
$349M
Beta
1.27
52-week high
$30.10
52-week low
$8.27
Average daily volume
678K
Financial strength
Current ratio
4.745
Quick ratio
3.661
Long term debt to equity
5.916
Total debt to equity
5.934
Interest coverage (TTM)
-6.07%
Profitability
EBITDA (TTM)
-28.211
Gross margin (TTM)
62.61%
Net profit margin (TTM)
-81.76%
Operating margin (TTM)
-69.17%
Effective tax rate (TTM)
0.05%
Revenue per employee (TTM)
$250,000
Management effectiveness
Return on assets (TTM)
-24.43%
Return on equity (TTM)
-226.52%
Valuation
Price to revenue (TTM)
7.921
Price to book
32.41
Price to tangible book (TTM)
-36.34
Price to free cash flow (TTM)
-10.703
Free cash flow yield (TTM)
-9.34%
Free cash flow per share (TTM)
-1.07
Growth
Revenue change (TTM)
25.86%
Earnings per share change (TTM)
47.79%
3-year revenue growth (CAGR)
24.89%
10-year revenue growth (CAGR)
23.18%
3-year earnings per share growth (CAGR)
11.68%
10-year earnings per share growth (CAGR)
-6.41%
What the Analysts think about ClearPoint Neuro
Analyst ratings (Buy, Hold, Sell) for ClearPoint Neuro stock.
Analyst projections of the future price of ClearPoint Neuro stock.
Bulls say / Bears say
The commercial device business is gaining traction: second-quarter revenue rose 18%, while neurosurgery navigation and therapy revenue grew 62% to $5.6 million, helped by IRRAflow and new operating-room navigation software. Capital equipment and software revenue also rose 24%, and gross margin improved to 62%. (ClearPoint Neuro)
ClearPoint has a broad partner pipeline moving towards potential commercial use. Management expects 10–15 trials using its technology to enrol patients over the next 18 months, alongside about 10 partner data readouts, while several partners have received positive FDA feedback on possible biologics licence submissions. (ClearPoint Neuro, ClearPoint Neuro)
The new ClearPoint Advanced Laboratories facility could add preclinical service revenue, with the first GLP services statement of work expected to finish in the first half of 2027. ClearPoint is also extending its platform through a 10-year focused-ultrasound partnership and has demonstrated tracer delivery across the blood-brain barrier in a preclinical model. (ClearPoint Neuro, ClearPoint Neuro)
The higher-growth biologics and drug-delivery segment weakened: its second-quarter revenue fell 15% because of lower shipments supporting new trial starts. ClearPoint also reduced its 2026 revenue guidance to $48–52 million as it shifts spending towards clinical support, regulatory work and product development. (ClearPoint Neuro, Investing.com)
The company is consuming cash faster than it is generating it. Cash fell to $29.4 million from $45.9 million at 2025 year-end after $15.0 million of operating cash use in the first half, while second-quarter operating expenses rose sharply and the net loss widened to about $11.3 million. (ClearPoint Neuro, ClearPoint Neuro)
Several important growth drivers remain unproven and are dependent on execution. The focused-ultrasound system is still at the preclinical stage, the robotics and Harmony software are in development, and the first GLP services work is not expected to complete until the first half of 2027, leaving room for delays before meaningful revenue arrives. (ClearPoint Neuro, ClearPoint Neuro)
Data summarised monthly by Lightyear AI. Last updated on 27 Sept 2026.
ClearPoint Neuro Financial Performance
Revenues and expenses
ClearPoint Neuro Earnings Performance
Company profitability
Upcoming events
No upcoming events
ClearPoint Neuro News
AllArticlesVideos
ClearPoint Neuro Q2 Earnings Call Highlights
MarketBeat2 months ago
ClearPoint Neuro Reports Second Quarter 2026 Results
Accesswire2 months ago
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
Accesswire2 months ago
Funds containing ClearPoint Neuro
AllEURGBP
Fund name | Fund size | $CLPT weighting |
|---|---|---|
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.